BeOne Medicines (ONC) Gross Profit (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Gross Profit of $1.3 billion for Q1 2026, up 41.37% year-over-year from $952.3 million in Q1 2025, and down 0.7% quarter-over-quarter from $1.4 billion in Q4 2025.
BeOne Medicines (ONC) Gross Profit (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Gross Profit for 10 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Profit rose 41.37% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $5.1 billion (up 43.11% YoY), while the FY2025 annual figure was $4.7 billion, up 45.34% from the prior year.
- Gross Profit eased to $1.3 billion in Q1 2026 per ONC's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Gross Profit topped out at $1.4 billion in Q4 2025 and bottomed at $241.4 million in Q1 2022.
- Historically, Gross Profit has averaged $732.1 million across 5 years, with a median of $685.0 million in 2023.
- On a YoY basis, Gross Profit climbed as much as 137.76% in 2022 and fell as far as 57.89% in 2022.
- BeOne Medicines' Gross Profit stood at $306.6 million in 2022, then jumped by 72.41% to $528.6 million in 2023, then surged by 82.99% to $967.3 million in 2024, then soared by 40.16% to $1.4 billion in 2025, then slipped by 0.7% to $1.3 billion in 2026.
- Business Quant data shows ONC's Gross Profit at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|